Pharmacological basis and clinical evidence of dabigatran therapy

Dabigatran is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. It has been approved in the European Union and the United States of America for the prevention of thrombosis after major orthopedic surgery. It has also been approved by the American Food and Drug Administ...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hematology and oncology 2011-12, Vol.4 (1), p.53-53, Article 53
Main Authors: Redondo, Santiago, Martínez, Maria-Paz, Ramajo, Marta, Navarro-Dorado, Jorge, Barez, Abelardo, Tejerina, Teresa
Format: Article
Language:English
Subjects:
Anticoagulants - pharmacokinetics
Anticoagulants - pharmacology
Anticoagulants - therapeutic use
Aspirin
atrial fibrillation
Atrial Fibrillation - drug therapy
Benzimidazoles - pharmacokinetics
Benzimidazoles - pharmacology
Benzimidazoles - therapeutic use
beta-Alanine - analogs & derivatives
beta-Alanine - pharmacokinetics
beta-Alanine - pharmacology
beta-Alanine - therapeutic use
Blood clot
Blood platelets
Bone surgery
Cardiac arrhythmia
Clinical trials
Cytochrome
Dabigatran
Dabigatran etexilate
Disease prevention
Drug dosages
Drug therapy
Enzymes
Health aspects
Hematology
Humans
Kidney diseases
Kidney Failure, Chronic - drug therapy
Oncology
Pharmacokinetics
Prevention
Review
Stroke (Disease)
surgery
Thromboembolism
Thrombosis
Thrombosis - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dabigatran is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. It has been approved in the European Union and the United States of America for the prevention of thrombosis after major orthopedic surgery. It has also been approved by the American Food and Drug Administration and the European Medicines Agency for the prevention of stroke in chronic atrial fibrillation. Dabigatran provides a stable anticoagulation effect without any need to perform periodical laboratory controls. Of note, there is a growing amount of clinical evidence which shows its safety and efficacy. For these reasons, dabigatran may suppose a revolution in oral anticoagulation. However, two important limitations remain. First, it is contraindicated in patients with end-stage renal disease. Second, there is no evidence of the prevention of thrombosis in mechanical heart valves.
ISSN:1756-8722
1756-8722
DOI:10.1186/1756-8722-4-53